Companies › Applied Biologics
3 active drug programs in 3 registered trials: 2 Phase 4, 1 Phase 3; Metabolic and endocrine, Immunology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XPURT Single-layer amniotic membrane | – | Phase 4 | Pressure Ulcer | Aug 2027 |
| XWRAP Single layer placental-based allograft | – | Phase 4 | Diabetic Foot | Aug 2027 |
| BIOxHEAL human amniotic membrane allograft | – | Phase 3 | Diabetic Foot Ulcer | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07159282 | XWRAP | Phase 4 | Diabetic Foot | Metabolic and endocrine | Aug 2027 |
| NCT07126886 | XPURT | Phase 4 | Pressure Ulcer | Immunology | Aug 2027 |
| NCT07852338 | BIOxHEAL | Phase 3 | Diabetic Foot Ulcer | Metabolic and endocrine | Sep 2027 |
No annotated target.
–
Sequence LifeScience Tiger Biosciences BioLab Holdings Yong Zhao, MD, PhD Spur Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.